SCHEMBL5000979

SCHEMBL5000979

Nc1ccc(C(=O)Cn2c(-n3ccc(N)n3)nc3ccccc32)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
F2R P25116 1/20 0.43
CTSD P07339 6/20 0.42
CXCR3 P49682 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
ALPL P05186 2/20 0.41
ALPG P10696 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALPP P05187 1/20 0.41
PLAA Q9Y263 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
GUSB P08236 2/20 0.41
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4996791 0.86 CXCR3 (0.57) SMN1; SMN2NPSR1CTSDCXCR3CYP2C9
SCHEMBL1818686 0.83 MAPT (0.59) SMN1; SMN2NPSR1CTSDTDP1LMNA
SCHEMBL5000985 0.83 SMN1; SMN2 (0.53) SMN1; SMN2NPSR1F2RCTSDCXCR3
SCHEMBL2581813 0.73 KDM4E (0.68) SMN1; SMN2MAPTTSHR
SCHEMBL1801571 0.70 CTSD (0.45) SMN1; SMN2NPSR1F2RCTSDCXCR3
SCHEMBL1802357 0.68 F2R (0.41) SMN1; SMN2NPSR1F2RCTSDCXCR3
SCHEMBL1800064 0.68 CTSD (0.46) SMN1; SMN2NPSR1F2RCTSDCXCR3
SCHEMBL11890510 0.68 KDM4E (0.52) SMN1; SMN2CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL14470429 0.66 F2R (0.61) SMN1; SMN2NPSR1F2RCTSDCXCR3
SCHEMBL1802857 0.65 CXCR3 (0.57) SMN1; SMN2NPSR1CTSDCXCR3CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287681-A1 Substituted Benzimidazoles and their Use for Inducing Apoptosis EBERLE MARTIN 2008-11-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287681-A1 Substituted Benzimidazoles and their Use for Inducing Apoptosis BAX, BCL2, BAD SMN1; SMN2 2693/4885NPSR1 4369/4885F2R 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.